SCHEMBL2495347

SCHEMBL2495347

COC(=O)c1cnc(Nc2cccnc2)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
ABL1 P00519 1/20 0.54
BCR P11274 1/20 0.54
SRC P12931 1/20 0.54
ALPL P05186 1/20 0.49
KDM4E B2RXH2 3/20 0.49
RAB9A P51151 2/20 0.49
HSD17B10 Q99714 1/20 0.49
HDAC6 Q9UBN7 2/20 0.48
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP19A1 P11511 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 1/20 0.47
HIF1A Q16665 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30923165 0.83 HDAC6 (0.55) ALDH1A1ABL1BCRKDM4ERAB9A
SCHEMBL2497628 0.83 HDAC6 (0.55) ALDH1A1ABL1BCRKDM4ERAB9A
SCHEMBL2499020 0.81 HDAC6 (0.50) ALDH1A1RAB9AHDAC6KMT2ACYP11B1
SCHEMBL30923250 0.81 F7 (0.56) ALPLRAB9AHDAC6CYP11B1CYP11B2
SCHEMBL10642215 0.79 KDM4E (0.56) ALDH1A1ABL1BCRSRCKDM4E
SCHEMBL30144037 0.78 ALDH1A1 (0.65) ALDH1A1ABL1BCRSRCKDM4E
SCHEMBL3226295 0.78 ALDH1A1 (0.65) ALDH1A1ABL1BCRSRCKDM4E
SCHEMBL22575205 0.77 CYP19A1 (0.52) ALDH1A1ABL1BCRSRCALPL
Methyl Nicotinate SCHEMBL24566 0.77 ALDH1A1 (1.00) ALDH1A1HSD17B10HDAC6KMT2ACYP19A1
Methyl Nicotinate SCHEMBL820747 0.77 ALDH1A1 (1.00) ALDH1A1HSD17B10HDAC6KMT2ACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 ALDH1A1 3119/4885ABL1 6/4885BCR 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.